PHARMACY BOARD[657]
[Prior to 2/10/88, see Pharmacy Examiners, Board of [620], renamed Pharmacy Examiners Board[657]
under the "umbrella" of Public Health Department by 1986 Iowa Acts, ch 1245; renamed by 2007 Iowa Acts, Senate File 74]

### CHAPTER 1 PURPOSE AND ORGANIZATION

	PURPOSE AND ORGANIZATION
1.1(17A)	Board mission
1.2(17A,147,272C)	Description and organization of board
1.3(17A,272C)	Responsibilities
1.4(17A,272C)	Submission of complaints and requests
1.5(17A,21)	Meetings
1.6(124,147,155A)	Fee for returned check
1.7(124,124B,147,1	55A) Overpayment of fees
	CHA PEED A
	CHAPTER 2
2 1 (1 47 155 A)	PHARMACIST LICENSES
2.1(147,155A)	Licensure by examination
2.2(155A)	Application for examination—requirements  Examination fee
2.3(147,155A)	
2.4(155A)	Internship requirements
2.5(155A)	College graduate certification
2.6(147)	Reexamination applications and fees Examination results
2.7(147)	
2.8(155A)	Transfer of examination scores
2.9(147,155A)	Licensure by license transfer/reciprocity
2.10(155A)	Foreign pharmacy graduates
2.11(147,155A)	License expiration and renewal
2.12(272C)	Continuing education requirements
2.13(272C)	Active and inactive license status Fees for additional license certificates
2.14(155A)	
2.15(155A)	Notifications to the board
2.16(235B,272C)	Mandatory training for identifying and reporting abuse
	CHAPTER 3
	PHARMACY TECHNICIANS
3.1(155A)	Definitions
3.2(155A)	Purpose of registration
3.3(155A)	Registration required
3.4	Reserved
3.5(155A)	Certification of pharmacy technicians
3.6(155A)	Extension of deadline for national certification
3.7	Reserved
3.8(155A)	Application form
3.9(155A)	Registration term and renewal
3.10(155A)	Registration fee
3.11(155A)	Late applications and fees
3.12(155A)	Registration certificates
3.13(155A)	Notifications to the board
3.14 to 3.16	Reserved
3.17(155A)	Training and utilization of pharmacy technicians
3.18(147,155A)	Identification of pharmacy technician

3.19

Reserved

3.20(155A) 3.21(155A) 3.22(155A) 3.23(155A) 3.24(155A) 3.25 to 3.27	Responsibility of supervising pharmacist Delegation of functions Technical functions Tasks a pharmacy technician shall not perform New prescription drug orders or medication orders Reserved			
3.28(147,155A) 3.29(155A) 3.30(155A)				
	CHAPTER 4 PHARMACIST-INTERNS			
4.1(155A)	Definitions  Definitions			
4.2(155A)	Goal and objectives of internship			
4.3(155A)	1500-hour requirements			
4.4(155A)	Iowa colleges of pharmacy clinical internship programs			
4.5(155A)	Out-of-state internship programs			
4.6(155A)	Registration, reporting, and authorized functions			
4.7(155A)	Foreign pharmacy graduates			
4.8(155A)	Fees			
4.9(155A)	Preceptor requirements			
4.10(155A)	Denial of pharmacist-intern registration			
4.11(155A)	Discipline of pharmacist-interns			
	CHAPTER 5			
	PHARMACY SUPPORT PERSONS			
5.1(155A)	Definitions			
5.2(155A)	Purpose of registration			
5.3	Reserved			
5.4(155A)	Registration required			
5.5(155A)	Exempt from registration			
5.6	Reserved			
5.7(155A)	Registration application form			
5.8	Reserved			
5.9(155A)	Registration fee			
5.10(155A)	Registration renewal			
5.11(155A) 5.12	Late application Reserved			
5.13(155A)	Registration certificates			
5.14(155A)	Notifications to the board			
5.15(155A)	Identification of pharmacy support person			
5.16	Reserved			
5.17(155A)	Tasks a pharmacy support person shall not perform			
5.18(155A)	Nontechnical pharmacy support tasks			
5.19	Reserved			
5.20(155A)	Training and utilization of pharmacy support persons			
5.21(155A)	Responsibility of supervising pharmacist			
5.22(155A)	Delegation of nontechnical functions			
5.23	Reserved			
5.24(155A)	Denial of registration			
5.25(147,155A)	Unethical conduct or practice			
5.26(155A)	Discipline of pharmacy support persons			

## CHAPTER 6 GENERAL PHARMACY PRACTICE

6.1(155A)	Purpose and scope
6.2(155A)	Pharmacist in charge
6.3(155A)	Reference library
6.4(155A)	Exemption from duplicate requirements
6.5 and 6.6	Reserved
6.7(124,155A)	Security
6.8(124,155A)	Prescription processing documentation
6.9(124,155A)	Transfer of prescription
6.10(126,155A)	Prescription label requirements
6.11 and 6.12	Reserved
6.13(155A)	Patient record system
6.14(155A)	Patient counseling and instruction
6.15(124,126)	Return of drugs and other items
6.16(124,155A)	Records

#### CHAPTER 7

#### HOSPITAL PHARMACY PRACTICE

7.1(155A)	Purpose and scope
7.2(155A)	Pharmacist in charge
7.3(155A)	Reference library
7.4 and 7.5	Reserved
7.6(124,155A)	Security
7.7(155A)	Verification by pharmacist when pharmacy is closed
7.8(124,126,155A)	Drug distribution and control
7.9(124,155A)	Drug information
7.10(124,155A)	Ensuring rational drug therapy
7.11(124,126,155A)	Outpatient services
7.12(124,126,155A	Drugs in the emergency department
7.13(124,155A)	Records

## CHAPTER 8

#### UNIVERSAL PRACTICE STANDARDS

8.1(155A)	Purpose and scope
8.2(155A)	Pharmaceutical care
8.3(155A)	Responsibility
8.4(155A)	Pharmacist identification
8.5(155A)	Environment and equipment requirements
8.6(155A)	Health of personnel
8.7(155A)	Procurement, storage, and recall of drugs and devices
8.8(124,155A)	Out-of-date drugs or devices
8.9(124,155A)	Records
8.10	Reserved
8.11(147,155A)	Unethical conduct or practice
8.12(126,147)	Advertising
8.13(135C,155A)	Personnel histories
8.14(155A)	Training and utilization of pharmacy technicians or pharmacy support persons
8.15(155A)	Delivery of prescription drugs and devices
8.16(124,155A)	Confidential information
8.17 and 8.18	Reserved

Manner of issuance of a prescription drug or medication order 8.19(124,126,155A)

8.20(155A) 8.21(155A) 8.22 to 8.25 8.26(155A) 8.27 to 8.31 8.32(124,155A) 8.33(147,155A) 8.34(155A) 8.35(155A)	Valid prescriber/patient relationship Prospective drug use review Reserved Continuous quality improvement program Reserved Individuals qualified to administer Supervision of pharmacists who administer adult immunizations Collaborative drug therapy management Pharmacy license
	CHAPTER 9
Α	AUTOMATED MEDICATION DISTRIBUTION SYSTEMS AND TELEPHARMACY SERVICES
9.1(155A)	Purpose and scope
9.2(147,155A)	Definitions
9.3(147,155A)	Pharmacist in charge responsibilities
9.4	Reserved
9.5(124,155A)	General requirements for telepharmacy
9.6(155A) 9.7 to 9.9	Duties of pharmacist in telepharmacy practice Reserved
9.7 to 9.9 9.10(147,155A)	Quality assurance and performance improvement
9.11(147,155A)	Policies and procedures
9.12(147,155A)	System, site, and process requirements
9.13(147,155A)	Records
9.14	Reserved
9.15(147,155A)	Decentralized unit dose AMDS
9.16(147,155A)	Centralized unit dose AMDS
9.17(147,155A)	Outpatient AMDS
9.18(124,155A)	Remote dispensing site operations
9.19	Reserved
9.20(124,155A)	Drugs at a remote dispensing site
9.21(124,155A)	Record keeping
	CHAPTER 10
	CONTROLLED SUBSTANCES
10.1(124)	Who shall register
10.2(124)	Application forms
10.3(124)	Registration and renewal
10.4(124)	Exemptions—registration fee Separate registration for independent activities; coincident activities
10.5(124) 10.6(124)	Separate registration for independent activities, coincident activities  Separate registrations for separate locations; exemption from registration
10.0(124) 10.7 to 10.9	Reserved
10.10(124,147,155	
10.11(124)	Modification or termination of registration
10.12(124)	Denial, modification, suspension, or revocation of registration
10.13 and 10.14	Reserved
10.15(124,155A)	Security requirements
10.16(124)	Report of theft or loss
10.17(124)	Accountability of stock supply
10.18(124)	Disposal
10.19 and 10.20	Reserved
10.21(124,126,155	A) Prescription requirements

10.22(124)	Schedule II emergency prescriptions		
10.23(124)	Schedule II prescriptions—partial filling		
10.24(124)	Schedule II medication order		
10.25(124)			
10.26	Reserved		
10.27(124,155A)	Facsimile transmission of a controlled substance prescription		
10.28(124,155A)	Schedule III, IV, or V refills		
10.29(124,155A)	Schedule III, IV, or V partial fills		
10.30(124,155A)	Schedule III, IV, and V medication order		
10.31(124,155A)	Dispensing Schedule V controlled substances without a prescription		
10.32(124,155A)	Dispensing products containing ephedrine, pseudoephedrine, or		
, , ,	phenylpropanolamine without a prescription		
10.33(124,155A)	Schedule II perpetual inventory in pharmacy		
10.34(124,155A)	Records		
10.35(124,155A)	Physical count and record of inventory		
10.36(124)	Samples and other complimentary packages—records		
10.37(124,126)	Revision of controlled substances schedules		
10.38(124)	Temporary designation of controlled substances		
` /			
10.39(124,126)	Excluded substances		
10.40(124,126)	Anabolic steroid defined		
10.41(124A)	Designation of imitation controlled substances		
	CHAPTER 11		
I	DRUGS IN EMERGENCY MEDICAL SERVICE PROGRAMS		
11.1(124,147A,155			
11.2(124,147A,155			
11.3(124,147A,155			
11.4(124,147A,155	•		
11.5(124,147A,155	,		
11.6(124,147A,155	<i>'</i>		
11.7(124,147A,155	*		
11.7(124,1471,133.	1) Security and condo		
	CHAPTER 12		
	PRECURSOR SUBSTANCES		
12.1(124B)	Precursor substance identified		
12.2(124B)	Reports required		
12.3(124B)	Form of reports		
12.4(124B)	Monthly reporting option		
12.5(124B)	Exemptions		
12.6(124B)	Identification of purchaser or other recipient		
12.7(124B)	Permits		
12.8(124B)	Denial, modification, suspension, or revocation of permit		
,			
	CHAPTER 13		
	STERILE COMPOUNDING PRACTICES		
13.1(124,126,155A)			
13.2(124,126,155A)			
13.3(155A)	Responsibilities		
13.4	Reserved		
13.5(155A)	References required		
13.6(126,155A)	Policies and procedures		
13.7(126,155A)	Labeling requirements		
13.8 and 13.9	Reserved		

13.10(126,155A)	Microbial contamination risk levels
13.11(155A)	Low-risk preparations and low-risk preparations with 12-hour or less beyond-use
	date
13.12(155A)	Medium-risk preparations
13.13(155A)	High-risk preparations
13.14(155A)	Immediate-use preparations
13.15(155A)	Utilization of single-dose and multiple-dose containers
13.16(155A)	Utilization of proprietary bag and vial systems
13.17 to 13.19	Reserved
13.20(124,155A)	Sterile preparation of hazardous drugs
13.21 and 13.22	Reserved
13.23(124,155A)	Verification of compounding accuracy and sterility
13.24(124,155A)	Sterilization methods
13.25(155A)	Media-fill testing by personnel
13.26	Reserved
13.27(124,126,155)	
13.28(155A)	Cleaning, maintenance, and supplies
13.29(126,155A)	Environmental monitoring requirements
13.30	Reserved
13.31(155A)	Quality assurance (QA)
13.32(155A)	Patient or caregiver education and training
13.33(124,155A)	Storage and delivery of sterile preparations
13.33(124,133A)	Storage and derivery of sterile preparations
	CHAPTER 14
	PUBLIC INFORMATION AND INSPECTION OF RECORDS
14.1(22,124,155A)	Definitions
14.2(22,124,155A)	Purpose and scope
14.3(22,124,155A)	
14.4(22,124,155A)	Access to confidential records
14.5(22,124,155A)	Requests for treatment of a record as a confidential record and its withholding
, , , , , , , ,	from examination
14.6(22,124,155A)	Procedure by which additions, dissents, or objections may be entered into
( , , , ,	certain records
14.7(22,124,155A)	Consent to disclosure by the subject of a confidential record
14.8(22,124,155A)	Notice to suppliers of information
14.9(22,124,155A)	Disclosures without the consent of the subject
14.10(22,124,155A	· ·
14.11(22,124,155A	
14.12(22,124,155A	
14.13(22,124,155A	
14.14(22,124,155A	,
14.15(22,124,155A	
14.16(22,124,155A	, 6 1
14.10(22,124,1337	) Computer
	CHAPTER 15
	CORRECTIONAL PHARMACY PRACTICE
15.1(155A)	Purpose and scope
15.2(126,155A)	Definitions
15.3(155A)	Pharmacist in charge
15.4(155A)	Reference library
15.5(124,155A)	Security
15.6	Reserved

15.7(124,126,155A 15.8(124,126,155A	Drug distribution and dispensing controls	
15.9 Reserved		
15.10(124,126,155	A) Policies and procedures	
	CHAPTER 16	
	NUCLEAR PHARMACY PRACTICE	
16.1(155A)	Purpose and scope	
16.2(155A)	Definitions	
16.3(155A)	General requirements for qualified nuclear pharmacist	
16.4(155A)	General requirements for pharmacies providing radiopharmaceutical services	
16.5(155A)	Library	
16.6(155A)	Minimum equipment requirements	
16.7(155A)	Training and utilization of pharmacy support persons	
	CHAPTER 17	
	WHOLESALE DRUG LICENSES	
17.1(155A)	Definitions	
17.2	Reserved	
17.3(155A)	Wholesale drug license	
17.4(155A)	Minimum qualifications	
17.5(155A)	Personnel	
17.6(155A)	Responsibility for conduct	
17.7(124,155A)	Distribution to authorized licensees	
17.8(124,155A)	Written policies and procedures	
17.9(155A)	Facilities	
17.10(124,155A)	Security	
17.11(155A)	Storage	
17.12	Reserved	
17.13(155A)	Drugs in possession of representatives	
17.14(155A)	Examination of materials	
17.15(155A)	Returned, damaged, and outdated prescription drugs	
17.16(124,155A)	Record keeping	
17.17(124,155A)	Compliance with federal, state, and local laws	
17.18(155A)	Discipline	
	CHAPTER 18	
C	CENTRALIZED PRESCRIPTION FILLING AND PROCESSING	
18.1(155A)	Purpose and scope	
18.2(155A)	Definitions	
18.3(155A)	General requirements	
18.4	Reserved	
18.5(155A)	Patient notification and authorization	
18.6 to 18.9	Reserved	
18.10(155A)	Policy and procedures	
18.11 to 18.14	Reserved	
18.15(155A)	Records	
	CHAPTER 19	
	NONRESIDENT PHARMACY PRACTICE	
19.1(155A)	Definitions	
19.2(155A)	Application and license requirements	
19.3(124,155A)	Applicability of board rules	

19.4 to 19.6 19.7(155A) 19.8(124,155A) 19.9(155A)	Reserved Confidential data Storage and shipment of drugs and devices Patient record system, prospective drug use review, and patient counseling
19.10(155A)	Discipline
	CHAPTER 20
	PHARMACY COMPOUNDING PRACTICES
20.1(124,126,155)	
20.2(124,126,155)	
20.3(124,126,155)	
20.4(126,155A)	Organization and personnel
20.5(126,155A)	Drug compounding facilities
20.6(126,155A)	Sterile products and radiopharmaceuticals
20.7	Reserved
20.8(126,155A)	Equipment
20.9(126,155A)	Control of bulk drug substances, components, containers, and closures
20.10(124,126,155	
20.11(126)	Bulk compounding (A) Records
20.12(124,126,155	A) Recolus
	CHAPTER 21
	ELECTRONIC DATA IN PHARMACY PRACTICE
21.1(124,155A)	Definitions
21.2(124,155A)	System security and safeguards
21.3(124,155A)	Verifying authenticity of an electronically transmitted prescription
21.4(124,155A)	Automated data processing system
21.5(124,155A)	Pharmacist verification of controlled substance refills—daily printout or logbook
21.6	Reserved Electronically prepared prescriptions
21.7(124,155A) 21.8(124,155A)	Computer-to-computer transmission of a prescription
21.9(124,155A) 21.9(124,155A)	Facsimile transmission (fax) of a prescription
21.10 and 21.11	Reserved
21.12(124,155A)	Prescription drug orders for Schedule II controlled substances
21.13(124,155A)	Prescription drug orders for Schedule II controlled substances—emergency
( , )	situations
21.14(124,155A)	Facsimile transmission of a prescription for Schedule II narcotic
	substances—parenteral
21.15(124,155A)	Facsimile transmission of Schedule II controlled substances—long-term care
	facility patients
21.16(124,155A)	Facsimile transmission of Schedule II controlled substances—hospice patients
	CHAPTER 22
UNIT	DOSE, ALTERNATIVE PACKAGING, AND EMERGENCY BOXES
22.1(155A)	Unit dose dispensing systems
22.2	Reserved
22.3(126)	Prepackaging
22.4	Reserved
22.5(126,155A)	Patient med paks
22.6	Reserved
22.7(124,155A)	Emergency/first dose drug supply
22.8	Reserved
22.9(155A)	Home health agency/hospice emergency drugs

# CHAPTER 23

LONG-TERM CARE PHARMACY PRACT	JONG-TERM	CARE	PHAKN	MACY.	PKA	CHCF
-------------------------------	-----------	------	-------	-------	-----	------

	LONG-TERM CARE PHARMACY PRACTICE
23.1(155A)	Definitions
23.2(124,155A)	Applicability of rules
23.3(124,155A)	Freedom of choice
23.4(124,155A)	Pharmacy responsibilities
23.5(124,155A)	Emergency drugs
23.6(124,155A)	Space, equipment, and supplies
23.7(124,155A)	Policies and procedures
23.8	Reserved
23.9(124,155A)	Medication orders
23.10(124,155A)	Stop orders
23.11(124,155A)	Drugs dispensed—general requirements
23.12	Reserved
23.13(124,155A)	Labeling drugs under special circumstances
23.14(124,155A)	Labeling of biologicals and other injectables supplied to a facility
23.15(124,155A)	Return and reuse of drugs and devices
23.16(124,155A) 23.16(124,155A)	Destruction of outdated and improperly labeled drugs
23.17(124,155A)	Accountability of controlled substances
23.17(124,135A) 23.18(124,155A)	Schedule II orders
23.19(124,155A) 23.19(124,155A)	Dispensing Schedule II controlled substances
23.20(124,155A)	Partial filling of Schedule II controlled substances
23.21(124,155A)	Destruction of controlled substances
23.21(124,133A)	Destruction of controlled substances
	CHAPTER 24
	Reserved
	CHAPTER 25
	CHILD SUPPORT NONCOMPLIANCE
25.1(252J)	Definitions
25.2(252J)	Issuance or renewal of license—denial
25.3(252J)	Suspension or revocation of a license
25.4(17A,22,252J)	Share information
	CHAPTER 26
	CHAPTER 26
	PETITIONS FOR RULE MAKING (Uniform Rules)
26.1(17A)	Petition for rule making
26.2(17A)	Briefs
26.3(17A)	Inquiries
26.4(17A)	Board consideration
20.1(1711)	Bould Colloradium
	CHAPTER 27
	DECLARATORY ORDERS
27.1(17.4)	(Uniform Rules)
27.1(17A)	Petition for declaratory order
27.2(17A)	Notice of petition
27.3(17A)	Intervention
27.4(17A)	Briefs
27.5(17A)	Inquiries
27.6(17A)	Service and filing of petitions and other papers
27.7(17A)	Consideration
27.8(17A)	Action on petition
27.9(17A)	Refusal to issue order

27.10(17A)	Contents of declaratory order—effective date
27.11(17A)	Copies of orders
27.12(17A)	Effect of a declaratory order
	CHAPTER 28
	AGENCY PROCEDURE FOR RULE MAKING
	(Uniform Rules)
28.1(17A)	Applicability
28.2(17A)	Advice on possible rules before notice of proposed rule adoption
28.3(17A)	Public rule-making docket
28.4(17A)	Notice of proposed rule making
28.5(17A)	Public participation
28.6(17A)	Regulatory analysis
28.7(17A,25B)	Fiscal impact statement
28.8(17A)	Time and manner of rule adoption
28.9(17A)	Variance between adopted rule and published notice of proposed rule adoption
28.10(17A)	Exemptions from public rule-making procedures
28.11(17A)	Concise statement of reasons
28.12(17A)	Contents, style, and form of rule
28.13(17A)	Board rule-making record
28.14(17A)	Filing of rules  Effectiveness of rules prior to publication
28.15(17A) 28.16(17A)	Effectiveness of rules prior to publication General statements of policy
28.17(17A)	Review by board of rules
20.17(17A)	Review by board of fules
	CHAPTER 29
	SALES OF GOODS AND SERVICES
29.1(68B)	Selling of goods or services by members of the board
29.2(68B)	Conditions of consent for board members
29.3(68B)	Authorized sales
29.4(68B)	Application for consent
29.5(68B)	Limitation of consent
	CHAPTER 30
	IMPAIRED PHARMACY PROFESSIONAL
	AND TECHNICIAN RECOVERY PROGRAM
30.1(155A)	Definitions
30.2(155A)	Purpose, function, and responsibilities
30.3(155A)	Program committee and personnel; confidentiality; liability
30.4(155A)	Identification and referral of impaired professionals and technicians
30.5(155A)	Recovery contract requirements
30.6(155A)	Program provider contract
30.7(155A)	Disclosure of information
30.8(155A)	Program funds
,	
	CHAPTER 31
	STUDENT LOAN DEFAULT OR NONCOMPLIANCE
01.1/0/13	WITH AGREEMENT FOR PAYMENT OF OBLIGATION
31.1(261)	Definitions
31.2(261)	Issuance or renewal of a license—denial
31.3(261)	Suspension or revocation of a license
31.4(17A,22,261)	Share information

### CHAPTER 32

#### NONPAYMENT OF STATE DEBT

	32.1(272D)	Definitions
1	32.2(272D)	Issuance or renewal of a license—denial
1	32.3(272D)	Suspension or revocation of a license
2	32.4(17A,22,272D)	Share information

#### CHAPTER 33 Reserved

#### CHAPTER 34

## RULES FOR WAIVERS AND VARIANCES

	ROLLS I OR WHIVERS THE VIRGINICES
34.1(17A)	Definition
34.2(17A,124,126,1	47,155A,205,272C) Scope of chapter
34.3(17A,124,126,1	47,155A,205,272C) Applicability of chapter
34.4(17A)	Criteria for waiver or variance
34.5(17A,124,126,1	47,155A,205,272C) Filing of petition
34.6(17A)	Content of petition
34.7(17A)	Additional information
34.8(17A)	Notice
34.9(17A)	Hearing procedures
34.10(17A)	Ruling
34.11(17A,22)	Public availability
34.12(17A)	Summary reports
34.13(17A)	Cancellation of a waiver
34.14(17A,124,126	,147,155A,205,272C) Violations
34.15(17A,124,126	,147,155A,205,272C) Defense
34.16(17A)	Judicial review

#### CHAPTER 35

#### **CONTESTED CASES**

25 1/17 4	104 104D	106 147 155 4	205 2720	C	1 1' 1'1'
35 I(I/A	124 124B	126 147 155A	. 205 272C)	Scope and	d applicability

35.2(17A,272C) Definitions

35.3(17A) Time requirements

35.4 Reserved

35.5(17A,124B,126,147,155A,205,272C) Notice of hearing

35.6(17A,272C) Presiding officer for nondisciplinary hearings

35.7(17A,124B,147,155A,272C) Waiver of procedures 35.8(17A,272C) Telephone or network proceedings

35.9(17A) Disqualification

35.10(17A,272C) Consolidation—severance

35.11(17A,272C) Service and filing of pleadings and other papers

35.12(17A,272C) Discovery 35.13(17A,272C) Subpoenas 35.14(17A,272C) Motions

35.15(17A,272C) Prehearing conference

35.16(17A,272C) Continuances 35.17(17A) Withdrawals 35.18 Reserved

35.19(17A,124B,126,147,155A,205,272C) Hearing procedures in contested cases

35.20(17A,272C) Evidence 35.21(17A,272C) Default

35.22(17A,272C) Ex parte communication

	Interlocutory appeals				
, ,	Final decision				
	26,147,155A,205,272C)	• •			
		Applications for rehearing			
	Stays of board actions				
	No factual dispute conto				
35.30(17A,124B,12	26,147,155A,205,272C)	Emergency adjudicative proceedings			
		CHAPTER 36			
		DISCIPLINE			
36.1(147,155A,272	C) Authority and grou	ands for discipline			
36.2(155A,272C)					
36.3(147,272C)	Peer review committees	$\mathbf{S}$			
36.4(17A,124,124E	3,126,147,155A,272С) Г	Disciplinary proceedings			
36.5(17A,124,124E	3,126,147,155A,272C) N	Notice of disciplinary hearing			
36.6(17A,124B,147	7,155A,272C) Informal s	settlement			
	Appearance				
36.8(17A,124B,147	7,155A,272C) Order of p	proceedings			
36.9(272C)	Confidentiality				
36.10(17A,272C)	Notification of decision				
36.11(272C)	Board decision				
36.12(17A,272C)	Publication of decisions	3			
36.13(17A,124B,14	47,155A,272C) Reinstate	ement			
36.14(17A,124B,14	47,155A,272C) Informal	reinstatement conference			
36.15(17A,124B,14	17,155A,272C) Voluntar	y surrender of a license, permit, or registration			
36.16(17A,124B,14	47,155A,272C) License,	permit, or registration denial			
36.17(155A,272C)	Order for mental or phy	vsical examination			
36.18(272C)	Disciplinary hearings—	fees and costs			
		CHAPTER 37			
		TION MONITORING PROGRAM			
37.1(124)	Purpose				
37.2(124)	Definitions				
37.3(124)	Requirements for the Pl	MP			
37.4(124)	Access to database info				
37.5(124)	Fees				
37.6(124)	PMP information retain	ed			
37.7(124)	Information errors				
37.8(124)	Dispenser and practition	ner records			
37.9(124)	Prohibited acts				
37.5(12.1)		A PETER G. A.C			
	СН	APTERS 38 to 99			
		Reserved			
	(	CHAPTER 100			
	TRA	LECTRONIC PSEUDOEPHEDRINE ACKING SYSTEM			
100.1(124)	Purpose and scope				
100.2(124)	Definitions				
100.3(124)	Electronic pseudoephedrine tracking system (PTS)				
100.4(124)	Access to database information and confidentiality				
100.5(124)	Violations				